Related News
Genzyme sees new drugs unveiled faster
GENZYME, a United States company specializing in treating rare diseases, said it expects new drugs to be introduced in China at a quicker pace in the future because awareness and knowledge of rare diseases among Chinese have improved over the years.
“Now China only accounts for less than 1 percent of Genzyme’s global sales, and we hope to work with government institutions and the healthcare system to work out a more sustainable way for treating rare diseases,” Genzyme Chief Executive David Meeker said in an interview with Shanghai Daily yesterday.
He added that awareness of rare diseases is picking up in China.
Genzyme, which first entered China in 1999, is now helping treat about 130 patients with Gaucher disease, a hereditary disease in which the metabolism and storage of fats is abnormal.
Meeker said Genzyme, part of French pharmaceutical giant Sanofi, expects to receive approval soon for its second drug in China to treat Pompe disease which damages muscle and nerve cells throughout a person’s body.
- About Us
- |
- Terms of Use
- |
- RSS
- |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证:沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证:31120180004
- |
- 网络视听许可证:0909346
- |
- 广播电视节目制作许可证:沪字第354号
- |
- 增值电信业务经营许可证:沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.